Compare L3Harris Technologies Inc (LHX) vs Pfizer Inc (PFE) Price & Performance

LHX trades at $236.92, up 1.41% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 7.34% net income margin. The company secured major defense contracts totaling over $10.7 billion recently, while technical indicators show bearish momentum despite positive analyst sentiment with a $340 consensus price target representing 44% upside potential.

LHX presents a compelling investment case with robust defense contract wins and improving profitability, though investors face headwinds from multiple law firm investigations and bearish technical signals. The stock's current valuation appears reasonable with a P/E of 23.93, but legal uncertainties require careful monitoring alongside the company's strong defense sector positioning.

Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.

The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.